Download PDF
Planta Med 2007; 73(5): 439-443
DOI: 10.1055/s-2007-967173
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Low Concentrations of Resveratrol Potentiate the Antiplatelet Effect of Prostaglandins

Chin-Chung Wu1 , Chung-I Wu1 , Wei-Ya Wang1 , Yang-Chang Wu1
  • 1Graduate Institute of Nature Products, Kaohsiung Medical University, Kaohsiung City, Taiwan, ROC
Further Information

Publication History

Received: November 29, 2006 Revised: February 24, 2007

Accepted: March 6, 2007

Publication Date:
04 April 2007 (online)

    Permissions and Reprints

Abstract

Resveratrol, a polyphenolic compound found in grapes and other fruits, is thought to contribute to the cardioprotective effect of red wine. While resveratrol exhibits some antiplatelet effect in vitro, the concentrations needed are much higher than those in plasma after consumption of red wine. In the present study, we investigate if resveratrol is able to potentiate the effect of endogenous antiplatelet substances - prostaglandin (PG) I2 and PGE1. In human platelet suspension resveratrol at relatively low concentrations (2 or 5 μM), which did not affect platelet function, significantly enhanced the inhibitory activity of PGs on platelet aggregation caused by collagen. The mechanisms underlying this effect may be associated with the inhibition of protein kinase C activation and protein tyrosine phosphorylation, but not with cyclic nucleotide levels and intracellular calcium mobilization in platelets. Our results might provide a possible explanation for the in vivo antiplatelet effect of resveratrol despite the poor bioavailability and the weak in vitro activity.

Key words

Resveratrol - prostaglandins - platelet aggregation - protein kinase C - protein tyrosine phosphorylation

References

  • 1 Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease.  Lancet. 1992;  339 1523-6.
    CrossrefPubMedGoogle Scholar
  • 2 Fremont L. Biological effects of resveratrol.  Life Sci. 2000;  66 663-73.
    CrossrefPubMedGoogle Scholar
  • 3 Olas B, Wachowicz B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions.  Platelets. 2005;  16 251-60.
    CrossrefPubMedGoogle Scholar
  • 4 Bertelli A A, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M. et al . Antiplatelet activity of synthetic and natural resveratrol in red wine.  Int J Tissue React. 1995;  17 1-3.
    PubMedGoogle Scholar
  • 5 Pace-Asciak C R, Hahn S, Diamandis E P, Soleas G, Goldberg D M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease.  Clin Chim Acta. 1995;  235 207-19.
    CrossrefPubMedGoogle Scholar
  • 6 Zini R, Morin C, Bertelli A, Bertelli A A, Tillement J P. Effects of resveratrol on the rat brain respiratory chain.  Drugs Exp Clin Res. 1999;  25 87-97.
    PubMedGoogle Scholar
  • 7 Baur J A, Sinclair D A. Therapeutic potential of resveratrol: the in vivo evidence.  Nat Rev Drug Discov. 2006;  5 493-506.
    CrossrefPubMedGoogle Scholar
  • 8 Mehta J, Mehta P. Role of blood platelets and prostaglandins in coronary artery disease.  Am J Cardiol. 1981;  48 366-73.
    CrossrefPubMedGoogle Scholar
  • 9 Wu C C, Hwang T L, Liao C H, Kuo S C, Lee F Y, Lee C Y. et al . The role of PAR4 in thrombin-induced thromboxane production in human platelets.  Thromb Haemost. 2003;  90 299-308.
    PubMedGoogle Scholar
  • 10 Grynkiewicz G, Poenie M, Tsien R T. A new generation of Ca2+ indicators with greatly improved fluorescence properties.  J Biol Chem. 1985;  260 3440-50.
    PubMedGoogle Scholar
  • 11 Wang W Y, Wu Y C, Wu C C. Prevention of platelet glycoprotein IIb/IIIa activation by a novel tyrosine kinase inhibitor 3,4-methylenedioxy-β-nitrostyrene.  Mol Pharmacol. 2006;  70 1380-9.
    CrossrefPubMedGoogle Scholar
  • 12 Schwarz U R, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides.  Biochem Pharmacol. 2001;  62 1153-61.
    CrossrefPubMedGoogle Scholar
  • 13 Hers I, Donath J, van Willigen G, Akkerman J W. Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure.  Arterioscler Thromb Vasc Biol. 1998;  18 404-14.
    PubMedGoogle Scholar
  • 14 Elzagallaai A, Rose S D, Trifaro J M. Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-derived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation.  Blood. 2000;  95 894-902.
    PubMedGoogle Scholar
  • 15 Osusky M, Taylor S J, Shalloway D. Autophosphorylation of purified c-Src at its primary negative regulation site.  J Biol Chem. 1995;  270 25 729-32.
    PubMedGoogle Scholar
  • 16 Shattil S J, Brass L F. Induction of the fibrinogen receptor on human platelets by intracellular mediators.  J Biol Chem. 1987;  262 992-1000.
    PubMedGoogle Scholar
  • 17 Sargeant P, Sage S O. Calcium signalling in platelets and other nonexcitable cells.  Pharmacol Ther. 1994;  64 395-443.
    CrossrefPubMedGoogle Scholar
  • 18 de Caffoy de Courcelles D. The role of protein kinase C in the human platelet.  Blood Coagul Fibrinolysis. 1990;  1 401-13.
    PubMedGoogle Scholar
  • 19 Slater S J, Seiz J L, Cook A C, Stagliano B A, Buzas C J. Inhibition of protein kinase C by resveratrol.  Biochim Biophys Acta. 2003;  1637 59-69.
    PubMedGoogle Scholar
  • 20 Della Bianca V, De Togni P, Grzeskowiak M, Vicentini L M, Di Virgilio F. Cyclic AMP inhibition of phosphoinositide turnover in human neutrophils.  Biochim Biophys Acta. 1986;  886 441-7.
    PubMedGoogle Scholar
  • 21 Jackson S P, Schoenwaelder S M, Yuan Y, Salem H H, Cooray P. Non-receptor protein tyrosine kinases and phosphatases in human platelets.  Thromb Haemost. 1996;  76 640-50.
    PubMedGoogle Scholar
  • 22 Rendu F, Eldor A, Grelac , Bachelot C, Gazit A, Gilon C. et al . Inhibition of platelet activation by tyrosine kinase inhibitors.  Biochem Pharmacol. 1992;  44 881-8.
    CrossrefPubMedGoogle Scholar
  • 23 Law D A, Nannizzi-Alaimo L, Ministri K, Hughes P E, Forsyth J, Turner M. et al . Genetic and pharmacological analyses of Syk function in αIIbβ3 signaling in platelets.  Blood. 1999;  93 2645-52.
    PubMedGoogle Scholar
  • 24 Kralisz U, Cierniewski C S. Activity of pp60c-src and association of pp60c-src, pp54/58lyn, pp60fyn, and pp72syk with the cytoskeleton in platelets activated by collagen.  IUBMB Life. 2000;  49 33-42.
    CrossrefPubMedGoogle Scholar
  • 25 Yu R, Hebbar V, Kim D W, Mandlekar S, Pezzuto J M, Kong A N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways.  Mol Pharmacol. 2001;  60 217-24.
    CrossrefPubMedGoogle Scholar
  • 26 Lin M T, Yen M L, Lin C Y, Kuo M L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.  Mol Pharmacol. 2003;  64 1029-36.
    CrossrefPubMedGoogle Scholar
  • 27 Harper M T, Sage S O. PAR-1-dependent pp60src activation is dependent on protein kinase C and increased [Ca2+]: evidence that pp60src does not regulate PAR-1-dependent Ca2+ entry in human platelets.  J Thromb Haemost. 2006;  4 2695-703.
    CrossrefPubMedGoogle Scholar
  • 28 Murugappan S, Shankar H, Bhamidipati S, Dorsam R T, Jin J, Kunapuli S P. Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets.  Blood. 2005;  106 550-7.
    CrossrefPubMedGoogle Scholar

Prof. Dr. Chin-Chung Wu or
Prof. Dr. Yang-Chang Wu

Graduate Institute of Nature Products

Kaohsiung Medical University

100 Shih-Chuan First Road

Kaohsiung City 807

Taiwan

Republic of China

Phone: +886-7-3121101 ext.2669

Email: ccwu@kmu.edu.tw

      >